Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Alvocidib + 7+3 in Newly Diagnosed AML
NCT03298984Phase 1Completed
- Sponsor
- Sumitomo Pharma America
- Start
- Sep 2017
- Primary completion
- Mar 2020
- Modality
- Orthosteric Ligands
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of alvocidib in acute myeloid leukemia (AML), sponsored by Sumitomo Pharma America. Primary endpoints: Maximum Tolerated Dose at Cycle 1 and Dose Limiting Toxicities at Cycle 1. Started Sep 2017; status: completed.
02
Drugs
alvocidib
03
Conditions
acute myeloid leukemia (AML)
Beyond the preview
Go deeper on NCT03298984.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03298984.